Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of MORAb-202 versus investigator’s choice chemotherapy in platinum-resistant high-grade serous ovarian cancer
jRCT2071220106Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of farletuzumab ecteribulin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Bristol Myers Squibb. Started Mar 2023; status: completed.
02
Drugs
farletuzumab ecteribulin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2071220106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220106.